Skip to main content
Myron R. Szewczuk PhD
 Myron R. Szewczuk
Position(s)
Professor
Contact Info
Botterell Hall, Room 828
613-770-6403

Faculty Bio

  • B.Sc. (Hons.) 1971 - University of Guelph; Physical chemistry
  • MSc 1972 - University of Guelph; Biochemistry and thermodynmics of protein-protein interactions. Supervisor - Dr. Rattray
  • PhD  1974- University of Windsor; Biology and immunochemistry. Supervisor - Dr. T.K. Mukkur
  • Killiam Post-doctoral Research Scholar - Cornell University Medical College, New York City, U.S.A. Cellular immunology, with Dr. Greg Siskind (01/1975 - 05/1977).
  • NIH Post-doctoral Research Scholar - Cornell University Medical College, New York City, U.S.A. Cellular immunology, with Dr. Greg Siskind (05/1977 - 06/1978).
  • Research Associate - Cornell University Medical College, New York City, U.S.A. Aging of the immune system, with Drs. Greg Siskind and Marc Weksler (09/1975 - 06/1978).
  • Assistant Professor - Department of Pathology and Host Resistance, McMaster University, Hamilton, Ontario (07/1978 - 06/1981)
  • Associate Professor - Department of Microbiology & Immunology, Queen's University, Kingston, Ontario (07/1981 - 06/1987)
  • Associate Professor - Department of Medicine, Queen's University, Kingston, Ontario (08/1988 - present)
  • Full Professor - Department of Micriobiology& Immunology, Queen's University, Kingston, Ontario (07/1987 - 06/2011)
  • Full Professor - Department of Biomedical & Molecular Sciences, Queen's University, Kingston, Ontario (07/2011 - present)
  • Appointed Honorable Editor-in-Chief - MOJ Polymer Science  (01/30/2018)

International Conference on Cancer Science and Therapeutics

Theme: Global Advances in Oncology & Cancer Research

DoubleTree by Hilton Hotel Orlando, August 13th-15th, 2020

CME Accredited

https://theresearchgate.com/conferences/cancer-science-therapeutics-2020/

Research interests:

  • Alternate therapeutic treatment of cancer. 
  • The role of glycosylation in the activation of neurotrophin Trk, EGFR, insulin and TOLL-like receptors. 
  • Molecular basis of Neu1 sialidase underlying TOLL-like receptor activation in pathophysiology of infections and inflammation. 
  • N-Acylated Hexosamines as Nutraceuticals: From Shellfish to Algae to Mammalian Bone and Joint Health. 
  • Trypanosome trans-sialidase for neuronal differentiation and neuroprotection from apoptosis
  • Biased G protein-coupled receptors agonism 
  • Insulin receptor in diseases
  • Medicinal Marijuana
  • Alternate therapeutic approach in the treatment of human cancer
  • The role of glycosylation in receptor activation
  • Molecular basis of Neu1 sialidase underlying TOLL-like receptor activation in pathophysiology of infections and inflammation
  • N-Acylated Hexosamines as Nutraceuticals: From Shellfish to Algae to Mammalian Bone and Joint Health
  • Trypanosome trans-sialidase for neuronal differentiation and neuroprotection from apoptosis


Details of Research Interests:

(A) Cancer Research:
The cancer research initiated and funded by a private-sector donor was focused to evaluate an alternate therapeutic approach in the treatment of human pancreatic cancer. This approach is based on our reports identifying the key players involved in ligand-binding and receptor activation to a novel receptor-signaling platform and its targeted translation in human disease. The cancer research identified for the first time that Neu1 sialidase may be an important cancer-targeting enzyme which acts at the receptor level signaling platform on the cell surface to modulate a number of glycosylated receptors such as epidermal growth factor, nerve growth factor TrkA, insulin and TOLL-like receptors, all of which are known to play major roles in cancer. We have identified an alternate treatment strategy being in the form of a horizontal approach, of which several important cancer growth factor receptor signaling platforms, oncogenic pathways, cancer cell survival in acquired chemo-resistance and macrophage-mediated tumor progression are targeted with promising therapeutic intent. International PCT/CA2011/050690 patent filing November 04, 2011 

(B) Inflammation
The mammalian Toll-like receptors (TLRs) are one of the families of sensor receptors that recognize pathogen-associated molecular patterns (PAMPs). Not only are TLRs crucial sensors of microbial (e.g., viruses, bacteria and parasite) infections for innate immune cells, they also play an important role in the pathophysiology of infectious, inflammatory and  autoimmune diseases. Thus, the intensity and duration of TLR responses against infections and inflammatory diseases must be tightly controlled.  Although the signaling pathways of TLR sensors are well characterized, the parameters controlling interactions between the sensors and their ligands still remain poorly defined. We have recently identified a novel mechanism of TLR activation by its natural ligand, which has not been previously observed (Amith et.al. 2009 Glycoconj J). It suggests that ligand-induced TLR activation is tightly controlled by Neu1 sialidase activation. Our data indicate that Neu1 sialidase is already in complex with TLR-2, -3 and -4 receptors, and is induced upon ligand binding to either receptor.  Activated Neu1 sialidase  then hydrolyzes  sialyl a-2,3-linked β-galactosyl residues distant from ligand binding to remove steric hinderance to TLR-4 dimerization, MyD88/TLR4 complex recruitment (Amith et.al. 2009 Cell Signaling), NFkB activation and pro-inflammatory cell responses (Amith et.al. 2009 Glycoconj J).  We know that neuraminidase inhibitor Tamiflu (oseltamivir phosphate) blocks TLR ligand induced NFkB activation, nitric oxide (NO) production and pro-inflammatory cytokines (Amith et.al. 2009 Glycoconj J). We have reported to date that TLR ligand binding induces a receptor conformational change to mediate GPCR-signaling via membrane Gαi-proteins and matrix metalloproteinase-9 (MMP-9) to activate Neu1. In addition, we have identified the key players involved in the activation of nucleic acid sensing intracellular TLR-7 and -9 receptors against imiquimod and CpG oligodeoxynucleotide (ODN), respectively. It discloses a striking identical signaling paradigm as described for the cell-surface TLRs and for receptor tyrosine kinases such as Trks, epidermal growth factor and insulin.   Here, Neu1 sialidase and matrix metalloproteinase-9 (MMP9) cross-talk in alliance with G-protein coupled receptor (GPCR) neuromedin-B tethered to TLR-7 and -9 receptors at the ectodomain forms a novel molecular organizational GPCR signaling platform that is essential for ligand activation of the TLRs and cellular signaling.  These findings radically redefine the current dogma(s) governing the essential activating molecules tethered to nucleic acid sensing TLRs as well as to cell surface sensing TLRs, which may provide pioneering molecular targeting approaches to disease intervention strategies.

(C) Insulin receptor signaling
We have uncovered  a novel Neu1 and matrix metalloproteinase-9 (MMP-9) cross-talk in alliance with neuromedin B G-protein coupled receptor (GPCR), which is essential for insulin-induced IR activation and cellular signaling. Neu1, MMP-9 and neuromedin B GPCR form a complex with IRβ subunit on the cell surface.  Our findings identify a novel insulin receptor-signaling platformthat is critically essential for insulin-induced IRβ tyrosine kinase activation and cellular signaling. 

Lab

Teaching Philosophy

  1. provide safe space to grow
  2. open career doors
  3. defend us when we needed it
  4. recognize and reward us
  5. develop us as leaders
  6. inspire us to stretch higher
  7. lead by example
  8. tell us our work matters
  9. forgive us when mistakes were made
  10. teach us how to think, not what to think
  11. Continue to remain a friend, mentor and guide.

Graduate Trainees

Ph.D. students
Fiona Haxho
Queen’s Graduate Award (QGA), the Graduate Entrance Tuition Award (GETA), the Natural Sciences and Engineering Research Council of Canada (NSERC) Alexander Graham Bell Canada Graduate Scholarship-Master’s (CGS M) and now the 2016 Vanier Canada Graduate Scholarship. (started MSc 09/14, mini-MSc defence 08/16 into PhD, successfully completed PhD Comprehensive exam June 20, 2017, successfully completed PhD dissertation defence July 31, 2017) - accepted MD program at University of Toronto starting September 2017.

Manpreet (Ruby) Sambi: Queen’s Graduate Award (QGA), and 2018 The Office of Postgraduate Medical Education Queen’s University Recognition Award.

Bessi Qorri: successfully completed the mini-Master (August 21, 2018). 
2018 Dean's Doctoral Award, 2017 Queen’s Graduate Award (QGA), 2017 Encyt Technologies, Inc., 2017 Terry Fox Research Institute Transdisciplinary Training Program in Cancer Research, and 2018 The Office of Postgraduate Medical Education Queen’s University Recognition Award.

M.Sc. students
Sabah Haq, M.D.Queen’s Graduate Award (QGA), and 2016 Ontario Graduate Scholarship (OGS) - (started September 2015 -completed June 21, 2017; accepted PhD position offer at McMaster University). 

Bessi Qorri: May 2017, successfully completed the mini-Master (August 21, 2018), Queen’s Graduate Award (QGA), Encyt Technologies, Inc. and  2017 Terry Fox Research Institute Transdisciplinary Training Program in Cancer Research

Vanessa Samuel: Combined BScH/MSc (declined). Accepted UBC MD program, MD offers at Calgary and Queen's

Nicka Kalaydina: September 2017, Queen’s Graduate Award (QGA), Encyt Technologies, Inc., and 2018 The Office of Postgraduate Medical Education Queen’s University Recognition Award. (completed August 2019).

Graduate Diploma and Professional Master in Medical Sciences (GDPM)

July 2017 January 2018 July 2018
Andrey Vishnyakov, MD Iryna Liauchonak, MD Arifuddin Saad Mohammed, MD
Anmol Lamba, MD Fady Dawoud, MBBCh Shamira Pira, MD
Catherine Nowierski, MSc, MD Yatin Riat, MD Jabiz Modaresi Esefh, MD, PhD
S.M. Signy Frank, MBBS Justin Jain, MD  
Umrao Bhatti, MBB Komal Bajwa, MBBS  
Yara Mouhamed, MBBCh    



GDPM Publications:

  1. Iryna Liauchonak1,4, Bessi Qorri2,4, Fady Dawoud1,4,Yatin Riat1,3,4, and Myron R. Szewczuk2,* Non-nutritive Sweeteners and their Implications on the Development of Metabolic Syndrome.  Nutrients 2019, 11, 644. http://dx.doi.org/10.3390/nu11030644  (impact factor 4.6, indexed PubMed). Received: 28 February 2019; Accepted: 13 March 2019 after extensive peer-review; Published:16 March 2019.  1Graduate Diploma and Professional Master in Medical Sciences, Postgraduate Medical Education, School of Medicine, Queen’s University, Kingston, ON, Canada; 2Department of Biomedical and Molecular Sciences, Queen’s University, Kingston, ON, Canada; 3Present address: Emergency Medicine, Resident Physician, Brooklyn Hospital Centre, 121 DeKalb Avenue, Brooklyn, N.Y. 11201, USA. 4Contributing first authorship
  2. Justin Jain1,3, Bessi Qorri2, 3 and Myron R. Szewczuk1,2,*The Crucial Role of Primary Care Providers in the Long-term follow up of Adult Survivors of Childhood Cancer. 2018 Cancer Management and Research (impact factor 3.702, indexed PubMed). submitted for publication December 09, 2018, under peer-review, accepted for publication February 02, 20192Department of Biomedical and Molecular Sciences, Queen’s University, Kingston, ON, Canada; 1Postgraduate Medical Education, Graduate Diploma and Professional Master in Medical Sciences, School of Medicine, Queen’s University, Kingston, ON, Canada; 3Contributing first authorship
  3. Regina-Veronicka Kalaydina1,4Komal Bajwa2,4, Bessi Qorri1,4, Alexandria Decarlo3, and Myron R. Szewczuk1,* Recent advances in “smart” delivery systems for extended drug release in cancer therapy. International Journal of Nanomedicine 2018:13 4727–4745, extensive peer-reviewed, indexed in PubMed Central  (impact factor: 5.008). DOI https://doi.org/10.2147/IJN.S168053.  1Department of Biomedical and Molecular Sciences, Queen’s University, Kingston, ON, Canada; 2Postgraduate Medical Education, Graduate Diploma and Professional Master in Medical Sciences, School of Medicine, Queen’s University, Kingston, ON, Canada; 3Department of Biology, Queen’s University, Kingston, ON, Canada; 4Contributing first authorship
  4. Iryna Liauchonak MD1,3, Fady Dawoud MBBCh1,3, Yatin Riat MD1,3, Bessi Qorri BSc2,3, Manpreet Sambi MSc2,3, Justin Jain MD1, Regina-Veronicka Kalaydina BSc2, Nicole Mendonza2, Komal Bajwa MBBS1, and Myron R. Szewczuk PhD2,*   Biased G-protein coupled receptor agonism bridges the gap between the insulin receptor and metabolic syndrome. Int. J. Mol. Sci. 2018, 19, 575.  (Impact factor: 3.2), indexed in PubMed Central; Received: 1 February 2018 / Revised: 11 February 2018 / Accepted: 15 February 2018 / Published: 17 February 2018. 1Postgraduate Medical Education, Graduate Diploma and Professional Master in Medical Sciences, School of Medicine, Queen’s University, Kingston, ON, Canada; 2 Department of Biomedical and Molecular Science, Queen’s University, Kingston ON, Canada;  3 Contributing first authorship.   doi:10.3390/ijms19020575
  5. Yara Mouhamed1,3, Andrey Vishnyakov1,3, Bessi Qorri2,3, Manpreet Sambi2,3, Signy Frank1, Catherine Nowierski1, Anmol Lamba1, Umrao Bhatti1, and Myron R Szewczuk2,*. Therapeutic Potential of Medicinal Marijuana: An Educational Primer for Healthcare Professionals. 2018 Drug, Healthcare and Patient Safety 10: 45–66indexed in PubMed Central; submitted 16/Jan/2018, extensive peer-review, accepted for publication March 9, 20181Postgraduate Medical Education, Graduate Diploma and Professional Master in Medical Sciences, School of Medicine, Queen’s University. 2Department of Biomedical and Molecular Sciences, Queen’s University. 3Contributing first authorship. https://www.dovepress.com/therapeutic-potential-of-medicinal-marijuana-an-educational-primer-for-peer-reviewed-article-DHPS
  6. Manpreet Sambi1,3, Bessi Qorri1,3, S.M. Signy Frank2, Yara Mouhamed2, Regina-Veronicka Kalaydina1, Nicole Mendonza1, and Myron R. Szewczuk1*. Novel Use of Peptides to Facilitate the Formation of 3D Multicellular Tumor Spheroids. 2017 Curr Top Pept Protein Res 18, 25-34indexed in PubMed Central; 1Department of Biomedical and Molecular Sciences, Queen’s University. 2Postgraduate Medical Education, Graduate Diploma and Professional Master in Medical Sciences, School of Medicine, Queen’s University. 3Contributing first authorship. http://www.researchtrends.net/tia/article_pdf.asp?in=0&vn=18&tid=26&aid…
     

Undergraduate 4th yr research project students

Shanel Mackay (2018-19): Life Sciences Specialization.

Alexandra DeCarlo (2018-19): Bachelor of Science, Specialization in Biotechnology (Honours)
Publications:

  1. Bessi Qorri1, Regina-Veronicka Kalaydina1, Aleksandra Velickovic1, Yekaterina Kaplya1, Alexandria Decarlo2, and Myron R. Szewczuk1,* Agonist-biased signaling via matrix metalloproteinase-9 promotes extracellular matrix remodeling. Cells 2018, 7, 117; http://dx.doi.org/10.3390/cells7090117 (impact factor 4.829);  full-text archived in PubMed Central. 1Department of Biomedical and Molecular Sciences, Queen’s University, Kingston, ON, Canada; 2Department of Biology, Biosciences Complex, Queen’s University, Kingston, ON, Canada K7L 3N6. *corresponding author
  2. Regina-Veronicka Kalaydina1,4, Komal Bajwa2,4, Bessi Qorri1,4, Alexandria Decarlo3, and Myron R. Szewczuk1,* Recent advances in “smart” delivery systems for extended drug release in cancer therapy. International Journal of Nanomedicine 2018:13 4727–4745, extensive peer-reviewed, indexed in PubMed Central (impact factor: 5.008)DOI https://doi.org/10.2147/IJN.S168053.  1Department of Biomedical and Molecular Sciences, Queen’s University, Kingston, ON, Canada; 2Postgraduate Medical Education, Graduate Diploma and Professional Master in Medical Sciences, School of Medicine, Queen’s University, Kingston, ON, Canada; 3Department of Biology, Queen’s University, Kingston, ON, Canada; 4Contributing first authorship
  3. Xia Li1,6 & Manpreet Sambi2,6, Alexandria DeCarlo3, Sergey V Burov4, Roman Akasov5, Elena Markvicheva5, Cecile Malardier-Jugroot1,* and Myron R Szewczuk2,* Functionalized folic acid-conjugated amphiphilic alternating copolymer actively targets 3D multicellular tumor spheroids and delivers the hydrophobic drug to the inner core. Nanomaterials 2018, 8, 588; doi:10.3390/nano8080588, extensive peer-reviewed, indexed in PubMed Central (Impact Factor: 3.811)1Department of Chemistry and Chemical Engineering, Royal Military College of Canada, Kingston, ON, Canada; 2Department of Biomedical and Molecular Sciences, Queen’s University, Kingston, ON, Canada; 3Department of Biology, Queen’s University, Kingston, ON, Canada; 4Synthesis of Peptides and Polymer Microspheres Laboratory, Institute of Macromolecular Compounds, Russian Academy of Sciences, St Petersburg, Russia; 5Department of Biomaterials and Biotechnologies, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia; 6Contributing first authors, *corresponding authors.

Vanessa Samuel  (2016-17): Life Sciences Specialization. Recipient of the Queen’s University Principal’s Scholarship and the Board of Governor’s Award.
Publications:

  1. Roman Akasov, Sabah Haq, Fiona Haxho, Vanessa Samuel, Sergey V. Burov, Elena Markvicheva, Ronald J. Neufeld, and Myron R. Szewczuk. Sialylation transmogrifies human breast and pancreatic cancer cells into 3D multicellular tumor spheroids using cyclic RGD peptide induced self-assembly. 2016 Oncotarget 2016, Vol. 7, No.40 66119-661342016. (impact factor 6.4)
  2. Manpreet Sambi, Sabah Haq, Vanessa Samuel, Bessi Qorri, Fiona Haxho, Kelli Hill, William Harless and Myron R. Szewczuk. Alternative therapies for metastatic breast cancer: multimodal approach targeting tumor cell heterogeneity. Breast Cancer - Targets and Therapy 2017:9 1–9.
  3. Sabah Haq, Fiona Haxho, Vanessa Samuel, Roman Akasov, Maria Leko, Sergey V. Burov, Elena Markvicheva and Myron R. Szewczuk.Sialylation facilitates self-assembly of 3D multicellular prostaspheres using cyclo-RGDfK(TPP) peptide. OncoTargets and Therapy 2017:10 2427–2447, accepted March 08, 2017, as it stands in current form.   DOI https://doi.org/10.2147/OTT.S133563

Bessi Qorri (2016-17): Life Sciences Specialization
Publications:

  1. Manpreet Sambi, Sabah Haq, Vanessa Samuel, Bessi Qorri, Fiona Haxho, Kelli Hill, William Harless and Myron R. Szewczuk. Alternative therapies for metastatic breast cancer: multimodal approach targeting tumor cell heterogeneity. Breast Cancer - Targets and Therapy 2017:9 1–9.
  2. Fiona Haxho1 & Manpreet Sambi1, Bessi Qorri1, William Harless, Myron R. Szewczuk. Current clinical challenges and emerging multi-modal approaches for the treatment of pancreatic cancer.  Clin Oncol. 2017; 2: 1296, submitted March 11, 2017, accepted for publication April 13, 2017 as it stands in current form.  1contributing first authors.
  3. Manpreet Sambi1,2 & Fiona Haxho1,2, Bessi Qorri1, William Harless3*, Myron R. Szewczuk1*. Pancreatic Adenocarcinoma: Current Therapies and Challenges. Adv Res Gastroentero Hepatol 4(4): ARGH.MS.ID.555643 (2017) 001, submitted April 15, 2017, accepted for publication April 18, 2017 as it stands in current form. 2contributing first authors. 3ENCYT Technologies, Inc. Membertou, NS, Canada. DOI: 10.19080/ARGH.2017.04.555643
  4. Manpreet Sambi1 & Bessi Qorri1 and Myron R Szewczuk. Therapeutic options for Metastatic Breast Cancer. Springer Book ‘Breast Cancer Metastasis and Drug Resistance’ – 2nd Volume, in preparation for July 2017 due date. 1contributing first authors.


All of my graduate students finish “on time, MSc 1.5 yrs and PhD 3yrs” with several publications in high impact (IF≥ 4.3) journals as first and contributing co-authors.

My undergrad 4th yr research project students and NSERC USRA funded students (~ 50%) have contributed as co-authors to our publications.

A high proportion of my trainees  have continued in academic or medical careers. Most gratifying and compelling success of my past PhD trainees are now academic faculty members as full professors and/or departmental heads or senior staff scientists in biotech companies.

My recent graduated PhD trainees have MD or post-doctoral positions (Dr. Fiona Haxho - MD program at the University of Toronto; Dr. Ray Amith- Post-doctoral training at the University of Alberta; Assistant Professor at Keele University, U.K.; Dr. Preethi Jayanth-Post-doctoral trainee at McMaster University); Dr. Samar Abdulkhalek-Post-doctoral training at Cleveland Clinic 1yr; Assistant Professor in UAE)

Lab members Bessi Qorri and Manpreet Sambi with Nobel Laureate Andrew Schally

The Nobel Prize in Physiology or Medicine 1977, Roger Guillemin, Andrew V. Schally, Rosalyn Yalow

Prize motivation: "for their discoveries concerning the peptide hormone production of the brain"

Aspects of Hypothalamic Regulation of the Pituitary Gland with Major Emphasis on Its Implications for the Control of Reproductive Processes

Books

Bessi Qorri, Manpreet Sambi, and Myron R Szewczuk (Editors). (2019) Current Applications for Overcoming Resistance to Targeted Therapies. Springer Nature Series (20): 250 pages. Publisher Springer Publisher Nature Series, New York, NY

Springer Nature Series eBook

Book Chapters

  1. Manpreet Sambi, Myron Szewczuk. (2019) Chapter 1: Introduction to the Acquisition of Resistance to Targeted Therapy. Editors M.R. Szewczuk, B. Qorri, M. Sambi. Current Applications for Overcoming Resistance to Targeted Therapies (20): 1-25. Publisher Springer Publisher Nature Series, New York, NY.
  2. Bessi Qorri, Myron R Szewczuk. (2019) Chapter 2: Targeting the Tumor Microenvironment to Overcome Resistance to Targeted Therapy. Editors M.R. Szewczuk, B. Qorri, M. Sambi. Current Applications for Overcoming Resistance to Targeted Therapies. (20): 25-65. Publisher Springer Publisher Nature Series, New York, NY.
  3. Manpreet Sambi, Bessi Qorri, William Harless and Myron R Szewczuk. (2019). Therapeutic options for Metastatic Breast Cancer. Editor Aamir Ahmad, Ph.D. Breast Cancer Metastasis and Drug Resistance. (2): 1-20. Publisher Springer Nature Series Book.
  4. Bessi Qorri1, Alexandria DeCarlo1, Cecile.Malardier-Jugroot2 and Myron R Szewczuk1.  (2019) Chapter 21: Drug delivery systems for cancer therapy. Editor Dr. Eric Chappel Debiotech SA, Microsystems Department, Lausanne 1004, Switzerland. Series Editor Dr. Dennis Fitzpatrick School of Computing and Engineering, University. Drug Delivery Devices and Therapeutic Systems 1-19. Publisher Elsevier. 1Dept. Biomedical and Molecular Sciences, Queen’s University, Kingston, Ontario K7L 3N6; 2Dept. of Chemistry and Chemical Engineering, Royal Military College of Canada, Kingston, ON K7K 7B4.
  5. Abdulkhalek, S., Amith, S.R. and Szewczuk, M.R. (2016). Role of glycosylation in TOLL-like receptor activation and pro-inflammatory responses. Editor Wiederschain, Gherman. Glycobiology and Diseases. 1-18. Publisher Taylor & Francis/CRC Press Publishing House.

Selected Publications

2019

  1. Bessi Qorri1, William Harless2, and Myron R Szewczuk1. Novel molecular mechanism of aspirin targeting neuraminidase-1 impedes epidermal growth factor receptor-signaling platform and induces apoptosis in pancreatic cancer cells. Scientific Reports under peer-review. (Impact factor 4.011, indexed PubMed), (Special Issue: Targeted Cancer Therapy). 1Department of Biomedical and Molecular Sciences, Queen’s University, Kingston, ON, Canada; 4Encyt Technologies, Inc., Membertou, NS, Canada.
  2. Manpreet Sambi1, Vanessa Samuel2, Bessi Qorri1, Sabah Haq3, Sergey V. Burov4, Elena Markvicheva5, William Harless4, and Myron R. Szewczuk1,*. A Triple Combination of Metformin, Acetylsalicylic Acid, and Oseltamivir Phosphate Significantly Impacts Tumor Spheroid Viability and Upends Chemoresistance in Triple-Negative Breast Cancer. Drug Design, Development and Therapy (Impact factor 3.208, indexed PubMed) under peer-review.  1Department of Biomedical and Molecular Sciences, Queen’s University, Kingston, ON, Canada; 2Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada; 3Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada; 4Laboratory of Novel Peptide Therapeutics, Cytomed J.S.Co., St-Petersburg, Russia; 5Biomedical Materials Laboratory, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia; 4Encyt Technologies, Inc., Membertou, NS, Canada.
  3. Regina-Veronicka Kalaydina1, Hedi Zhou1, Elena Markvicheva2, Sergey V Burov3, Farhana Zulkernine4, and Myron R Szewczuk1,*. Impact of fucosylation on self-assembly of prostate and breast tumor spheroids by using cyclo-RGDfK(TPP) peptide and image object detection. 2019 OncoTargets and Therapy 12, 11153–11173 (Impact factor 3.046, indexed PubMed). 1Department of Biomedical and Molecular Sciences, Queen’s University, Kingston, Ontario, Canada; 2 Biomedical Materials Laboratory, Shemyakin-Ovchinnikov, Institute of Bioorganic Chemistry, Russia, Moscow, Ul. Miklukho-Maklaya 16/10; 3Laboratory of Novel Peptide Therapeutics, Cytomed J.S.Co., St-Petersburg, Russia; 4School of Computing, Queen’s University, Kingston, ON. Canada.
  4. Manpreet Sambi1, Alexandria DeCarlo1, Cecile Malardier-Jugroot2,* and Myron R. Szewczuk1,*. Next-Generation Multimodality of Nanomedicine Therapy: Size and Structure Dependence of Folic Acid Conjugated Copolymers Actively Target Cancer Cells in Disabling Cell Division and Inducing Apoptosis. Cancers 2019, 11, 1698; doi:10.3390/cancers11111698. (Impact factor 6.1, indexed PubMed), (Special Issue Cancer Nanomedicine). 1Department of Biomedical and Molecular Sciences, Queen’s University, Kingston, ON K7L 3N6, Canada; 2Department of Chemistry and Chemical Engineering, Royal Military College of Canada, Kingston, ON K7K 7B4, Canada. https://doi.org/10.3390/cancers11111698
  5. Manpreet Sambi1, Leila Bagheri1,2 and Myron R Szewczuk1Current Challenges in Cancer Immunotherapy: Multimodal Approaches to Improve Efficacy and Patient Response Rates. 2019 Journal of Oncology, Volume 2019, Article ID 4508794, 12 pages, (Open Special Issue-Immunotherapy), (Impact factor: 4.528; indexed PubMed),  1Department of Biomedical and Molecular Sciences, Queen’s University, Kingston, ON, Canada2Present address: Postdoctoral Fellow, Research Laboratories in Sciences, Applied to Food, Canadian Irradiation Center, Universite du Quebec, INRS-Institue Armand-Frappier, 531, boul. des Prairies, Laval, QC, H7V 1B7, Canada. https://doi.org/10.1155/2019/4508794
  6. Iryna Liauchonak1,4, Bessi Qorri2,4, Fady Dawoud1, Yatin Riat1,3,4, and Myron R. Szewczuk2,*. Non-nutritive Sweeteners and their Implications on the Development of Metabolic Syndrome.  Nutrients 2019, 11, 644.   (Impact factor 4.6, indexed PubMed). 1Graduate Diploma and Professional Master in Medical Sciences, Postgraduate Medical Education, School of Medicine, Queen’s University, Kingston, ON, Canada; 2Department of Biomedical and Molecular Sciences, Queen’s University, Kingston, ON, Canada; 3Present address: Emergency Medicine, Resident Physician, Brooklyn Hospital Centre, 121 DeKalb Avenue, Brooklyn, N.Y. 11201, USA4Contributing first authorship http://dx.doi.org/10.3390/nu11030644 &nbsp
  7. Justin Jain1,*, Bessi Qorri2,* and Myron R Szewczuk2. The Crucial Role of Primary Care Providers in the Long-term follow up of Adult Survivors of Childhood Cancer. Cancer Management and Research 2019:11 3411–3418.  (Impact factor 3.702, indexed PubMed). 1Postgraduate Medical Education, Graduate Diploma and Professional Master in Medical Sciences, School of Medicine, Queen’s University, Kingston, ON, Canada; 2Department of Biomedical and Molecular Sciences, Queen’s University, Kingston, ON, Canada; *Contributing first authorship https://doi.org/10.2147/CMAR.S197644

2018

  1. Bessi Qorri1, Regina-Veronicka Kalaydina1, Aleksandra Velickovic1, Yekaterina Kaplya1, Alexandria Decarlo2 and Myron R. Szewczuk1. Agonist-biased signaling via matrix metalloproteinase-9 promotes extracellular matrix remodeling. Cells 2018, 7, 117 (Impact factor 4.829; indexed in PubMed).  1Department of Biomedical and Molecular Sciences, Queen’s University, Kingston, ON, Canada; 2Department of Biology, Biosciences Complex, Queen’s University, Kingston, ON, Canada K7L 3N6. http://dx.doi.org/10.3390/cells7090117
  2. Regina-Veronicka Kalaydina1,4, Komal Bajwa2,4, Bessi Qorri1,4, Alexandria Decarlo3 and Myron R. Szewczuk1. Recent advances in “smart” delivery systems for extended drug release in cancer therapy. International Journal of Nanomedicine 2018:13 4727–4745. (Impact factor: 5.008, indexed in PubMed)1Department of Biomedical and Molecular Sciences, Queen’s University, Kingston, ON, Canada; 2Postgraduate Medical Education, Graduate Diploma and Professional Master in Medical Sciences, School of Medicine, Queen’s University, Kingston, ON, Canada; 3Department of Biology, Queen’s University, Kingston, ON, Canada; 4Contributing first authorship https://doi.org/10.2147/IJN.S168053.
  3. Xia Li1,6 , Manpreet Sambi2,6, Alexandria DeCarlo3, Sergey V Burov4, Roman Akasov5, Elena Markvicheva5, Cecile Malardier-Jugroot1 and Myron R Szewczuk2.  Functionalized folic acid-conjugated amphiphilic alternating copolymer actively targets 3D multicellular tumor spheroids and delivers the hydrophobic drug to the inner core. Nanomaterials 2018, 8, 588. (Impact factor 4.358, indexed PubMed). 1Department of Chemistry and Chemical Engineering, Royal Military College of Canada, Kingston, ON, Canada; 2Department of Biomedical and Molecular Sciences, Queen’s University, Kingston, ON, Canada; 3Department of Biology, Queen’s University, Kingston, ON, Canada; 4Synthesis of Peptides and Polymer Microspheres Laboratory, Institute  Macromolecular Compounds, Russian Academy of Sciences, St Petersburg, Russia; 5Department of Biomaterials and Biotechnologies, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia; 6Contributing first authors. doi:10.3390/nano8080588
  4. Iryna Liauchonak, MD1,3, Fady Dawoud, MBBCh1,3, Yatin Riat, MD1,3, Bessi Qorri2,3, Manpreet Sambi2,3, Justin Jain, MD1, Regina-Veronicka Kalaydina2, Nicole Mendonza2, Komal Bajwa, MBBS1, and Myron R. Szewczuk2.   Biased G-protein coupled receptor agonism bridges the gap between the insulin receptor and metabolic syndrome. Int. J. Mol. Sci. 2018, 19, 575.  (Impact factor: 3.2; indexed in PubMed). 1Postgraduate Medical Education, Graduate Diploma and Professional Master in Medical Sciences, School of Medicine, Queen’s University, Kingston, ON, Canada; 2Department of Biomedical and Molecular Science, Queen’s University, Kingston ON, Canada; 3Contributing first authorship. https://doi:10.3390/ijms19020575
  5. Kurt Wood1, Myron R. Szewczuk2, Dérick Rousseau3 and Ronald J. Neufeld1Oseltamivir phosphate released from injectable Pickering emulsions over extended term disables human pancreatic cancer cell survival. Oncotarget 2018, Vol. 9, (No. 16), pp: 12754-12768. (Impact factor 5.168, indexed in PubMed). 1Chemical Engineering, Queen's University. 2Department of Biomedical and Molecular Science, Queen’s University, Kingston ON, Canada; 3Department of Chemistry and Biology, Ryerson University, Toronto, Ontario, Canada, M5B 2K3. https://doi.org/10.18632/oncotarget.24339
  6. Fiona Haxho, Sabah Haq and Myron R. Szewczuk. Biased G protein-coupled receptor agonism mediates Neu1 sialidase and matrix metalloproteinase-9 cross-talk to induce transactivation of insulin receptor signaling. 2018 Cellular Signalling 43, 71-84 (Impact factor 4.2, indexed in PubMed). Department of Biomedical and Molecular Science, Queen’s University, Kingston ON, Canada https://doi.org/10.1016/j.cellsig.2017.12.006
  7. Yara Mouhamed1,3, Andrey Vishnyakov1,3, Bessi Qorri2,3, Manpreet Sambi2,3, Signy Frank1, Catherine Nowierski1, Anmol Lamba1, Umrao Bhatti1, and Myron R Szewczuk2Therapeutic Potential of Medicinal Marijuana: An Educational Primer for Healthcare Professionals. 2018 Drug, Healthcare and Patient Safety 10: 45–66, (Indexed in PubMed Central PMID:29928146). 1Postgraduate Medical Education, Graduate Diploma and Professional Master in Medical Sciences, School of Medicine, Queen’s University. 2Department of Biomedical and Molecular Sciences, Queen’s University. 3Contributing first authorship. https://www.dovepress.com/therapeutic-potential-of-medicinal-marijuana-an-educational-primer-for-peer-reviewed-article-DHPS

2017

  1. Myron R Szewczuk. Biased G protein-coupled receptor agonism and mammalian neuraminidase 1-mediated glycosylated receptor signaling platform. J Glycobiol 2017, 6:2(Suppl). Department of Biomedical and Molecular Sciences, Queen’s University. DOI: 10.4172/2168-958X-C1-008
  2. Manpreet Sambi1,#, Bessi Qorri1,#, S. M. Signy Frank2, Yara Mouhamed2, Regina-Veronicka Kalaydina1, Nicole Mendonza1 and Myron R. Szewczuk1,*. Novel Use of Peptides to Facilitate the Formation of 3D Multicellular Tumor Spheroids. 2017 Curr Top Pept Protein Res 18, 25-341Department of Biomedical and Molecular Sciences, Queen’s University. 2Postgraduate Medical Education, Graduate Diploma and Professional Master in Medical Sciences, School of Medicine, Queen’s University. #Contributing first authorship. http://www.researchtrends.net/tia/article_pdf.asp?in=0&vn=18&tid=26&aid…
  3. Regina-Veronicka Kalaydina1,2, Bessi Qorri1,2, Myron R. Szewczuk1. Preventing Negative Shifts in Gut Microbiota with Cannabis Therapy: Implications for Colorectal Cancer. Adv. Res. Gastroentero. Hepatol.  2017; 7(3): 555712. 1Department of Biomedical and Molecular Sciences, Queen’s University. 2contributing first authors. DOI: 004 10.19080/ARGH.2017.07.555712
  4. Sabah Haq1,2,3, Manpreet Sambi1,3, Bessi Qorri1,3, Nicole Mendonza1,3 and Myron R. Szewczuk1. Aberrant Sialic Acid Expression and its Role in Regulating Metastasis in Colorectal Cancer. Adv Res Gastroentero Hepatol 2017; 7(2): 555707. 1Department of Biomedical and Molecular Sciences, Queen's University, Canada; 2Department of Pathology and Molecular Medicine, McMaster University, Canada; 3Contributing first authorship. http://dx.doi.org/10.19080/argh.2017.07.555707
  5. Bessi Qorri1,2, Manpreet Sambi1,2, Myron R. Szewczuk1Gut Microbiota and its Implications on the Progression of Gastrointestinal Cancer. Adv Res Gastroentero Hepatol 6(5):ARGH.MS.ID.555696 (2017). 1Department of Biomedical and Molecular Sciences, Queen’s University, Kingston, Canada. 2Contributing first authorship, Canadahttp://dx.doi.org/10.19080/argh.2017.06.555696
  6. Manpreet Sambi1,2, Bessi Qorri1,2, Cecile Malardier-Jugroot3, and Myron R. Szewczuk1. Advancements in Polymer Science: ‘Smart’ Drug Delivery Systems for the Treatment of Cancer. 2017 MOJ Poly Sci 1(3): 00016. 3 Head, Department of Chemistry and Chemical Engineering, Sawyer Mod 5, Rm 5512, Royal Military College of Canada, PO Box 17000, Station Forces Kingston, ON K7K 7B4, Canada. 2contributing first authors. DOI: 10.15406/mojps.2017.01.00016
  7. Manpreet Sambi1,2 & Fiona Haxho1,2, Bessi Qorri1,2, William Harless3*, Myron R. Szewczuk1*. Pancreatic Adenocarcinoma: Current Therapies and Challenges. 2017 Adv Res Gastroentero Hepatol 4(4): ARGH.MS.ID.555643 (2017) 001submitted April 15, 2017, accepted for publication April 18, 2017 as it stands in current form. 2contributing first authors. 3ENCYT Technologies, Inc. Membertou, NS, Canada. https://juniperpublishers.com/argh/pdf/ARGH.MS.ID.555643.pdf
  8. Stephanie N. Allison Logan1,2, Amanda J. Brissenden1, Myron R. Szewczuk3, and Ronald J. Neufeld1. Combinatorial and sequential delivery of gemcitabine and oseltamivir phosphate from implantable poly (lactic-co-glycolic acid) cylinders disables human pancreatic cancer cell survival. Drug Design, Development and Therapy 2017 Volume 2017:11 Pages 2239—2250submitted March 24, 2017, published 31 July 2017.  1Chemical Engineering, Queen's University. 2Polymer Science Group, Department of Chemical and Biomolecular Engineering, University of Melbourne, Parkville, Victoria 3010, Australia. DOI https://doi.org/10.2147/DDDT.S137934 
  9. Fiona Haxho1#, Manpreet Sambi1#, Bessi Qorri1#, William Harless2 and Myron R. Szewczuk1. Current clinical challenges and emerging multi-modal approaches for the treatment of pancreatic cancer.  Clin Oncol. 2017;2: 1296. (Impact factor 1.92, indexed PubMed). 1Department of Biomedical and Molecular Sciences, Queen’s University, Kingston, ON, Canada; 2ENCYT Technologies, Inc. Membertou, NS, Canada. #These authors have contributed equally. http://clinicsinoncology.com/
  10. Sabah Haq, Fiona Haxho, Vanessa Samuel, Roman Akasov, Maria Leko, Sergey V. Burov, Elena Markvicheva and Myron R. Szewczuk.Sialylation facilitates self-assembly of 3D multicellular prostaspheres using cyclo-RGDfK(TPP) peptide. OncoTargets and Therapy 2017:10 2427–2447, accepted March 08, 2017as it stands in current form. http://www.ncbi.nlm.nih.gov/pubmed/28496342
  11. Manpreet Sambi, Sabah Haq, Vanessa Samuel, Bessi Qorri, Fiona Haxho, Kelli Hill, William Harless and Myron R. Szewczuk. Alternative therapies for metastatic breast cancer: multimodal approach targeting tumor cell heterogeneity. Breast Cancer - Targets and Therapy 2017:9 1–9. Received 23rd December 2016Accepted 15th February 2017 as it stands in current form. DOI https://doi.org/10.2147/BCTT.S130838
  12. Manpreet Sambi and Myron R. Szewczuk. KRAS mutations: efficacy and sensitivity of early predictive screening of cancer progression require other gene mutations in addition to KRAS. Translational Cancer Research 2017;6(Suppl 1) S15-S17. Received 8th December 2016, Accepted 11th December 2016 as it stands in current form. DOI: http://dx.doi.org/10.21037/tcr.2017.01.05

Intellectual Property Patents

COMPOSITIONS AND METHODS FOR CANCER TREATMENT
Application No. PCT/CA2017/050768
Patent Status: Granted/Issued
Year Issued: June 22, 2017
Inventors: William W. Harless, M.D., Ph.D. and CEO Encyt Technologies, Inc. and Myron R Szewczuk, Ph.D.
Agent: NORTON ROSE FULBRIGHT CANADA LLP, 1 Place Ville Marie, Suite 2500, Montreal, Quebec H3B lRl, Canada
Canadian Intellectual Property Office (RO/CA)

METHOD TO IMPROVE THE EFFECTIVENESS OF ANTI-CANCER THERAPIES BY EXPOSING CANCER CELLS TO AN INFLAMMATORY STIMULUS PRIOR TO TREATMENT
Application No. PCT/CA2017/ 050765
Patent Status: Granted/Issued
Year Issued: June 22, 2017
Inventors: William W. Harless, M.D., Ph.D. and CEO Encyt Technologies, Inc. and Myron R Szewczuk, Ph.D.
Agent: NORTON ROSE FULBRIGHT CANADA LLP, 1 Place Ville Marie, Suite 2500,Montreal, Quebec H3B lRl, Canada
Canadian Intellectual Property Office (RO/CA)

Use of Neu1 Sialidase Inhibitors in the Treatment of Cancer.
Patent Application based on PCT/CA2011/050690. 2014/07/07.
Patent Status: Granted/Issued
Year Issued: 2014
Canada Patent

Use of Neu1 Sialidase Inhibitors in the Treatment of Cancer.
Application No. 11874886.2. 2014/07/07.
Patent Status: Granted/Issued - Application No./Patent No. 11874886.2 - 1112 / 2773340
Year Issued: 2014
European Patent

Use of Neu1 Sialidase Inhibitors in the Treatment of Cancer.
Patent Application based on PCT/CA2011/050690. 2014/07/07.
Patent Status: Granted/Issued
Year Issued: 2014
Chinese Patent

Use of Neu1 Sialidase Inhibitors in the Treatment of Cancer
Patent Application No. 14/370,916. 2014/07/07.
Patent Status: Granted/Issued - Pub. No.: US 2015/0064282 A1
Year Issued: 2014
United States Patent
 

USE OF OSELTAMIVIR PHOSPHATE AND ANALOGUES THEREOF FOR THE TREATMENT OF CANCER
Inventors: Myron R. Szewczuk, Ph.D. and Paul Josefowitz
Filing Serial No.: PCT/CA2011/050690, November 04, 2011
International Patent Cooperation Treaty (PCT)

Method for treating cancer with alternating 60 Hertz non-ionizing magnetic fields.
Inventors: Myron R. Szewczuk, Ph.D., William C. Morris, B.Sc. and John C. Beal, Ph.D. 
Filing Serial No.: February 16, 1993.
UNITED STATES PATENT

HIV Marker/ AIDS Vaccine
Inventors: Myron R. Szewczuk, Ph.D., Rashid H. Khan, M.D., Ph.D. and Douglas K. MacFadden, M.D., Ph.D. 
Filing Serial No.: November 19, 1990.
International Patent Cooperation Treaty (PCT)

Method for evaluating effective immunity against HIV infection and spread
Inventors: Myron R. Szewczuk, Ph.D., Rashid H. Khan, M.D., Ph.D. and Douglas K. MacFadden, M.D., Ph.D. 
Filing Serial No.: Canada; November 14, 1990; U.S.A.; November 14, 1990; February 9, 1993
Canada and United States Patents

Method for evaluating protection to bee venom.
Inventors: Myron R. Szewczuk, Ph.D., Rashid H. Khan, M.D., Ph.D. and James H. Day, M.D.
Filing Serial No.: 2,002,811-4; Canada; Nov 10, 1989, 442,910; U.S.A.; Nov 28, 1989.
UNITED STATES PATENT: Patent Number - 5,124,249, Date of patent - June 23, 1992